Q3 2018 EPS Estimates for Allergan plc Increased by Analyst (AGN)

Allergan plc (NYSE:AGN) – Analysts at SunTrust Banks increased their Q3 2018 EPS estimates for shares of Allergan in a research report issued on Monday, October 15th. SunTrust Banks analyst J. Boris now forecasts that the company will post earnings per share of $4.13 for the quarter, up from their previous forecast of $4.12. SunTrust Banks has a “Buy” rating and a $218.00 price target on the stock.

Allergan (NYSE:AGN) last announced its earnings results on Thursday, July 26th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the business posted $4.02 earnings per share. Allergan’s revenue was up 2.3% compared to the same quarter last year.

Several other brokerages also recently commented on AGN. Zacks Investment Research downgraded Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 3rd. ValuEngine raised Allergan from a “strong sell” rating to a “sell” rating in a report on Friday, September 21st. TheStreet raised Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Cowen set a $255.00 target price on Allergan and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $180.00 target price on shares of Allergan in a report on Friday, September 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $211.91.

Shares of NYSE AGN opened at $188.89 on Thursday. Allergan has a 12 month low of $142.81 and a 12 month high of $197.00. The firm has a market cap of $64.66 billion, a PE ratio of 11.55, a P/E/G ratio of 1.47 and a beta of 1.19. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85.

A number of hedge funds have recently modified their holdings of AGN. Boltwood Capital Management increased its holdings in shares of Allergan by 5.6% during the 3rd quarter. Boltwood Capital Management now owns 5,081 shares of the company’s stock valued at $967,000 after acquiring an additional 270 shares during the last quarter. Parkside Investments LLC increased its holdings in shares of Allergan by 1.8% during the 2nd quarter. Parkside Investments LLC now owns 15,845 shares of the company’s stock valued at $2,830,000 after acquiring an additional 275 shares during the last quarter. Avestar Capital LLC increased its holdings in shares of Allergan by 25.1% during the 2nd quarter. Avestar Capital LLC now owns 1,483 shares of the company’s stock valued at $230,000 after acquiring an additional 298 shares during the last quarter. New Jersey Better Educational Savings Trust increased its holdings in shares of Allergan by 9.4% during the 2nd quarter. New Jersey Better Educational Savings Trust now owns 3,500 shares of the company’s stock valued at $584,000 after acquiring an additional 300 shares during the last quarter. Finally, Parallel Advisors LLC increased its holdings in shares of Allergan by 34.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,233 shares of the company’s stock valued at $205,000 after acquiring an additional 319 shares during the last quarter. 77.38% of the stock is currently owned by institutional investors.

In other news, Director Joseph H. Boccuzi bought 900 shares of the company’s stock in a transaction on Thursday, August 30th. The shares were bought at an average cost of $190.59 per share, with a total value of $171,531.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction on Thursday, September 6th. The stock was purchased at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.37% of the stock is currently owned by insiders.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Featured Article: Marijuana Stocks Investing Considerations

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply